Programmed cell death protein 1 (PD-1) blockade is effective in the treatment of Hodgkin’s lymphoma (HL), and cytotoxic T lymphocyte associated antigen 4 (CTLA4) immunotherapy has shown significant antitumor effects in melanoma [6]. Here, CTLA4 is linked to Hodgkins lymphoma.